Table 2

Prespecified safety outcomes and other serious adverse events

	rhTNK-tPA			rt-PA	P value
	0.1 mg/kg (N=60)	0.25 mg/kg (N=57)	0.32 mg/kg (N=60)	0.9 mg/kg (N=59)	P value
Symptomatic ICH at 36 hours (ECASS III)	3 (5.0)	0 (0.0)	2 (3.3)	1 (1.7)	0.52
Death	6 (10.0)	1 (1.8)	5 (8.3)	6 (10.2)	0.22
Asymptomatic intracranial haemorrhage	4 (6.7)	3 (5.3)	5 (8.3)	2 (3.4)	0.75
Other extracranial bleeding	18 (30.0)	18 (31.6)	22 (36.7)	14 (23.7)	0.49
Serious adverse events	12 (20.0)	7 (12.3)	11 (18.3)	14 (23.7)	0.46

ECASS, European Cooperative Acute Stroke Study; ICH, intracranial haemorrhage; rhTNK-tPA, recombinant human tenecteplase tissue-type plasminogen activator.